Drug:
Reaction: DISEASE PROGRESSION
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26534422 |
IN |
60 | 1 |
Off label use, Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 102 | 26534602 |
EU |
||
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 103 | 26534603 |
US |
1 | |
Disease progression, |
||||
FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 104 | 26534928 |
SG |
1 | |
Disease progression, Product use issue, |
||||
DAROLUTAMIDE, |
||||
| 105 | 26535069 |
NZ |
1 | |
Disease progression, Off label use, |
||||
ATEZOLIZUMAB, |
||||
| 106 | 26535152 |
EU |
||
Immunotoxicity, Disease progression, |
||||
DURVALUMAB, |
||||
| 107 | 26535218 |
EU |
||
Illness, Disease progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 108 | 26527050 |
CN |
60 | 1 |
Disease progression, Febrile neutropenia, White blood cell count decreased, Lymphocyte count decreased, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), THALIDOMIDE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, |
||||
| 109 | 26527157 |
EU |
1 | |
Disease progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 110 | 26527272 |
VN |
44 | 1 |
Disease progression, Therapy non-responder, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
| 111 | 26527443 |
RU |
64 | 1 |
Therapy partial responder, Disease progression, |
||||
TRASTUZUMAB, TRASTUZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 112 | 26527497 |
US |
||
Disease progression, Necrosis, |
||||
GENTAMICIN, GENTAMICIN SULFATE, AMPICILLIN, AMPICILLIN SODIUM, AMPICILLIN INJECTION, CEFTAZIDIME, |
||||
| 113 | 26527506 |
US |
42 | 2 |
Disease progression, Dyspnoea, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 114 | 26527574 |
EU |
50 | 2 |
Disease progression, Investigation abnormal, |
||||
MIRVETUXIMAB SORAVTANSINE, |
||||
| 115 | 26527827 |
75 | 1 | |
Disease progression, Drug ineffective, Off label use, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE, ABATACEPT, IPILIMUMAB, NIVOLUMAB, |
||||
| 116 | 26527922 |
GB |
1 | |
Disease progression, |
||||
BENDAMUSTINE HCL, BENDAMUSTINE HCL, POLATUZUMAB VEDOTIN, |
||||
| 117 | 26528023 |
JP |
60 | 1 |
Chronic graft versus host disease, Disease progression, |
||||
BELUMOSUDIL, |
||||
| 118 | 26528024 |
JP |
72 | 1 |
Chronic graft versus host disease, Disease progression, |
||||
| 119 | 26528123 |
US |
||
Urinary tract infection, Multiple sclerosis, Disease progression, Bone pain, |
||||
OCRELIZUMAB, |
||||
| 120 | 26528389 |
CN |
35 | 1 |
Disease progression, |
||||
METHIMAZOLE, METHIMAZOLE, |
||||
| 121 | 26528588 |
EU |
43 | 1 |
Death, Cytokine release syndrome, Tumour lysis syndrome, Disease progression, |
||||
OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GLOFITAMAB, GLOFITAMAB, GLOFITAMAB, GLOFITAMAB, OBINUTUZUMAB, OBINUTUZUMAB, OBINUTUZUMAB, OBINUTUZUMAB, |
||||
| 122 | 26528785 |
PH |
48 | 2 |
Disease progression, |
||||
DOXORUBICIN, CISPLATIN, |
||||
| 123 | 26528914 |
US |
22 | 2 |
Disease progression, End stage renal disease, Off label use, |
||||
PREDNISONE, CYCLOSPORINE, |
||||
| 124 | 26529015 |
1 | ||
Disease progression, |
||||
CABAZITAXEL, PREDNISONE, |
||||
| 125 | 26529041 |
RU |
2 | |
Disease progression, |
||||
TRASTUZUMAB, ADO-TRASTUZUMAB EMTANSINE, |
||||
| 126 | 26529198 |
EU |
1 | |
Disease progression, |
||||
BENDAMUSTINE HCL, RITUXIMAB, |
||||
| 127 | 26529224 |
EU |
80 | 1 |
Disease progression, Drug ineffective, |
||||
SORAFENIB, SORAFENIB, SORAFENIB, SORAFENIB, |
||||
| 128 | 26529351 |
12 | ||
Disease progression, Adverse drug reaction, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 129 | 26529354 |
50 | ||
Disease progression, Off label use, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 130 | 26529427 |
US |
75 | |
Myelofibrosis, Disease progression, |
||||
RUXOLITINIB, |
||||
| 131 | 26529461 |
GB |
||
Death, Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 132 | 26529507 |
EU |
1 | |
Disease progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 133 | 26529876 |
US |
2 | |
Hyperglycaemia, Ill-defined disorder, Quality of life decreased, Disease progression, |
||||
INAVOLISIB, |
||||
| 134 | 26530025 |
GB |
1 | |
Pneumothorax, Urosepsis, Prostate cancer, Disease progression, Post procedural complication, |
||||
NINTEDANIB, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, HYDROXYCHLOROQUINE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, METHYLPREDNISOLONE, |
||||
| 135 | 26530192 |
CA |
51 | |
Pancreatic carcinoma metastatic, Disease progression, Superficial vein thrombosis, Off label use, |
||||
PEMIGATINIB, |
||||
| 136 | 26530251 |
EU |
73 | 1 |
Pelvic venous thrombosis, Disease progression, Pericardial effusion, Interstitial lung disease, Aortic aneurysm, Interstitial lung disease, Pneumonia, Diarrhoea, Weight decreased, Decreased appetite, |
||||
NINTEDANIB, NINTEDANIB, HYDROXYCHLOROQUINE, LEFLUNOMIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OXYGEN, 0XYGEN, METHYLPREDNISOLONE, |
||||
| 137 | 26533054 |
62 | 1 | |
Disease progression, |
||||
RETIFANLIMAB-DLWR, BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, CYCLOBENZAPRINE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, LISINOPRIL, PANTOPRAZOLE SODIUM, |
||||
| 138 | 26522683 |
TR |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 139 | 26522746 |
66 | 2 | |
Disease progression, Surgery, Intestinal obstruction, Vomiting, Nausea, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, OLANZAPINE, ZOLBETUXIMAB, ZOLBETUXIMAB, ZOLBETUXIMAB, ZOLBETUXIMAB, |
||||
| 140 | 26522799 |
EU |
||
Disease progression, Intentional product use issue, |
||||
RITUXIMAB, BENDAMUSTINE HCL, |
||||
| 141 | 26522929 |
US |
1 | |
Pulmonary mass, Gastric ulcer, Disease progression, |
||||
OSILODROSTAT, OSILODROSTAT, OSILODROSTAT, |
||||
| 142 | 26523104 |
EU |
34 | 2 |
Off label use, Disease progression, |
||||
BEVACIZUMAB, |
||||
| 143 | 26523237 |
CA |
51 | 1 |
Bacterial infection, Disease progression, Glioblastoma, Product use in unapproved indication, |
||||
BEVACIZUMAB, BEVACIZUMAB, |
||||
| 144 | 26523609 |
EU |
28 | 2 |
Post transplant lymphoproliferative disorder, Disease recurrence, Disease progression, Post transplant lymphoproliferative disorder, Diffuse large B-cell lymphoma, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, AZATHIOPRINE, CANDESARTAN, METOPROLOL TARTRATE, METOPROLOL, |
||||
| 145 | 26523726 |
AU |
2 | |
Prescribed overdose, Diabetes mellitus, Disease progression, Adrenal insufficiency, Blood pressure inadequately controlled, Vision blurred, Condition aggravated, Abdominal distension, Oedema peripheral, Therapeutic product effect variable, |
||||
OSILODROSTAT, OSILODROSTAT, OSILODROSTAT, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, MITOTANE, MITOTANE, MITOTANE, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, IRBESARTAN, HYDRALAZINE HYDROCHLORIDE, PREGABALIN, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, |
||||
| 146 | 26524148 |
BR |
||
Death, Abdominal mass, Ascites, Disease progression, Therapy partial responder, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 147 | 26524348 |
TH |
47 | 2 |
Neutropenia, Drug ineffective for unapproved indication, Disease progression, Hepatic enzyme increased, Product prescribing issue, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CAPECITABINE, CAPECITABINE, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, OXALIPLATIN, OXALIPLATIN, CARBOPLATIN, CARBOPLATIN, |
||||
| 148 | 26524354 |
EU |
64 | 2 |
Drug ineffective, Disease progression, |
||||
LENALIDOMIDE, CARFILZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 149 | 26524395 |
64 | 2 | |
Interstitial lung disease, Disease progression, Stomatitis, Platelet count decreased, Oedema peripheral, |
||||
DATOPOTAMAB DERUXTECAN, DATOPOTAMAB DERUXTECAN, EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL, MOUTHWASH, MENTHOL, METHYL SALICYLATE, THYMOL, EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL, MOUTHWASH, MENTHOL, METHYL SALICYLATE, THYMOL, |
||||
| 150 | 26524863 |
US |
72 | |
Myelodysplastic syndrome, Disease progression, Off label use, |
||||
RUXOLITINIB, |
||||
| 151 | 26525006 |
1 | ||
Gallbladder disorder, Feeling abnormal, Disease progression, |
||||
PEXIDARTINIB HYDROCHLORIDE, |
||||
| 152 | 26525062 |
JP |
7 | 1 |
Disease progression, Scrotal oedema, |
||||
ZONGERTINIB, |
||||
| 153 | 26525215 |
US |
1 | |
Calculus bladder, Disease progression, Diplopia, Walking aid user, Fatigue, Muscle spasms, Pain in extremity, Sleep disorder, Confusional state, |
||||
RAVULIZUMAB, RAVULIZUMAB, |
||||
| 154 | 26525427 |
JP |
42 | 1 |
Chronic graft versus host disease, Disease progression, |
||||
BELUMOSUDIL, |
||||
| 155 | 26525713 |
JP |
||
Disease progression, Off label use, |
||||
NINTEDANIB, NINTEDANIB, NINTEDANIB, |
||||
| 156 | 26525827 |
PK |
72 | 2 |
Disease progression, Asthenia, |
||||
BEVACIZUMAB, |
||||
| 157 | 26525856 |
LB |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 158 | 26525983 |
IN |
67 | 1 |
Off label use, Toxicity to various agents, Disease progression, |
||||
ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, |
||||
| 159 | 26525986 |
66 | 1 | |
Disease progression, |
||||
REGORAFENIB, |
||||
| 160 | 26526475 |
EU |
75 | 1 |
Drug ineffective, Disease progression, |
||||
DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, |
||||
| 161 | 26522408 |
TR |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 162 | 26521187 |
US |
38 | 1 |
Disease progression, Acute kidney injury, Drug resistance, |
||||
POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, ISAVUCONAZONIUM SULFATE, VORICONAZOLE, VORICONAZOLE INJECTION, AMPHOTERICIN B, AMPHOTERICIN B, |
||||
| 163 | 26521517 |
EU |
2 | |
Disease progression, |
||||
MIRVETUXIMAB SORAVTANSINE, |
||||
| 164 | 26521862 |
US |
70 | 2 |
Multiple organ dysfunction syndrome, Disease progression, Drug ineffective, |
||||
RIFAMPIN, ISONIAZID, PYRAZINAMIDE, GOLIMUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ETOPOSIDE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, |
||||
| 165 | 26521880 |
EU |
1 | |
Death, Disease progression, Diffuse large B-cell lymphoma, Leukopenia, |
||||
OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, RITUXIMAB, |
||||
| 166 | 26517349 |
VN |
71 | 2 |
Disease progression, Therapy non-responder, |
||||
ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 167 | 26517353 |
CA |
2 | |
Disease progression, Treatment failure, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, METHOTREXATE, METHOTREXATE SODIUM, ROFLUMILAST, |
||||
| 168 | 26517356 |
CA |
39 | 1 |
Basal cell carcinoma, Disease progression, Drug ineffective, Dysgeusia, Major depression, Muscle spasms, Musculoskeletal pain, Myalgia, |
||||
VISMODEGIB, VISMODEGIB, SONIDEGIB, CEMIPLIMAB-RWLC, |
||||
| 169 | 26517439 |
VN |
55 | 1 |
Disease progression, Therapy non-responder, |
||||
ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, |
||||
| 170 | 26517485 |
JP |
36 | 1 |
Disease progression, |
||||
BELUMOSUDIL, |
||||
| 171 | 26517783 |
GB |
69 | 1 |
Disease progression, Nausea, Vomiting, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMBROLIZUMAB, |
||||
| 172 | 26517861 |
JP |
7 | 2 |
Disease progression, Disease recurrence, |
||||
CAPECITABINE, CAPECITABINE, DOXORUBICIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 173 | 26517864 |
EU |
63 | 2 |
Disease progression, |
||||
DOXORUBICIN, MELPHALAN HYDROCHLORIDE, MELPHALAN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, CARMUSTINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYTARABINE, CYTARABINE, ETOPOSIDE, ETOPOSIDE, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, BLEOMYCIN, BLEOMYCIN SULFATE, |
||||
| 174 | 26517984 |
EU |
50 | 1 |
Rheumatoid nodule, Disease progression, Condition aggravated, |
||||
METHOTREXATE SODIUM, |
||||
| 175 | 26518015 |
EU |
47 | |
Disease progression, |
||||
BEVACIZUMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 176 | 26518085 |
EU |
80 | 2 |
Disease progression, Follicular lymphoma refractory, |
||||
BENDAMUSTINE HCL, BENDAMUSTINE HCL, DOXORUBICIN, DOXORUBICIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 177 | 26518640 |
ZA |
1 | |
Disease progression, Muscular weakness, Fatigue, |
||||
RITUXIMAB, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 178 | 26518913 |
US |
70 | 2 |
Multiple organ dysfunction syndrome, Disease progression, Cell-mediated cytotoxicity, Off label use, |
||||
ETOPOSIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, GOLIMUMAB, RIFAMPIN, ISONIAZID, PYRAZINAMIDE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, |
||||
| 179 | 26518919 |
US |
||
Subgaleal haematoma, Disease progression, Skin necrosis, Abscess, Skin exfoliation, |
||||
AMPICILLIN, AMPICILLIN SODIUM, AMPICILLIN INJECTION, CEFTAZIDIME, GENTAMICIN, GENTAMICIN SULFATE, |
||||
| 180 | 26519327 |
EU |
2 | |
Diffuse large B-cell lymphoma, Disease progression, General physical health deterioration, Drug ineffective, |
||||
OXALIPLATIN, OXALIPLATIN, RITUXIMAB, RITUXIMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 181 | 26519356 |
TR |
63 | 1 |
Disease progression, |
||||
ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 182 | 26519361 |
JP |
9 | 2 |
Disease progression, Neuropathy peripheral, Fatigue, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 183 | 26519406 |
US |
||
Disease progression, Acute myeloid leukaemia, Drug ineffective, Disease recurrence, |
||||
AZACITIDINE, AZACITIDINE FOR, |
||||
| 184 | 26519495 |
US |
||
Disease progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, |
||||
| 185 | 26519512 |
GB |
2 | 2 |
Disease progression, |
||||
CARBOPLATIN, ETOPOSIDE, THIOTEPA, |
||||
| 186 | 26519690 |
US |
||
Thrombotic microangiopathy, Prostate cancer recurrent, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, BICALUTAMIDE, LEUPROLIDE, LEUPROLIDE, DAROLUTAMIDE, CARBOPLATIN, OLAPARIB, ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 187 | 26519936 |
IN |
||
Disease progression, |
||||
| 188 | 26520129 |
US |
2 | |
Cerebrovascular accident, Blood glucose increased, Blood pressure increased, Fatigue, Disease progression, |
||||
OSILODROSTAT, OSILODROSTAT, OSILODROSTAT, OSILODROSTAT, SPIRONOLACTONE, SPIRONOLACTONE, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LISINOPRIL, MAGNESIUM HYDROXIDE, POLYETHYLENE GLYCOL 3350, ONDANSETRON HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, APREPITANT, FOSAPREPITANT DIMEGLUMINE, FAMOTIDINE, CETIRIZINE HYDROCHLORIDE, OLANZAPINE, OLANZAPINE PAMOATE, ROSUVASTATIN CALCIUM, INSULIN GLARGINE-YFGN, INSULIN GLARGINE, INSULIN ASPART, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, MAGNESIUM, |
||||
| 189 | 26520152 |
96 | 2 | |
Disease progression, |
||||
PIMAVANSERIN TARTRATE, CALCIUM, MEMANTINE, MEMANTINE HYDROCHLORIDE, MIRTAZAPINE, ROPINIROLE, THIAMINE HYDROCHLORIDE, ERGOCALCIFEROL, LISINOPRIL, LATANOPROST, TIOTROPIUM BROMIDE INHALATION SPRAY, |
||||
| 190 | 26520224 |
EU |
63 | |
Disease progression, Metastases to liver, Jaundice, Pyrexia, Hepatic function abnormal, Therapeutic response decreased, Pyrexia, Rash, |
||||
TEBENTAFUSP, TEBENTAFUSP, |
||||
| 191 | 26520330 |
GB |
76 | 1 |
Death, Myocarditis, Biliary obstruction, Cholelithiasis, Disease progression, Therapy non-responder, |
||||
CEMIPLIMAB-RWLC, |
||||
| 192 | 26520699 |
US |
||
Metabolic dysfunction-associated steatohepatitis, Disease progression, Hepatic cirrhosis, |
||||
RESMETIROM, |
||||
| 193 | 26520825 |
US |
81 | |
Gait disturbance, Pain, Hypoaesthesia, Trigger finger, Disease progression, |
||||
VUTRISIRAN, DIFLUNISAL, |
||||
| 194 | 26520833 |
US |
||
Hepatic cirrhosis, Metabolic dysfunction-associated steatohepatitis, Disease progression, |
||||
RESMETIROM, |
||||
| 195 | 26521059 |
2 | ||
Disease progression, Diarrhoea, Product use issue, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, PERTUZUMAB, |
||||
| 196 | 26512439 |
RU |
72 | 1 |
Death, Disease progression, |
||||
NINTEDANIB, NINTEDANIB, |
||||
| 197 | 26512506 |
AU |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 198 | 26512534 |
JP |
64 | 1 |
Disease progression, |
||||
ZANUBRUTINIB, |
||||
| 199 | 26512537 |
TH |
||
Neoplasm, Cytopenia, Disease progression, |
||||
GLOFITAMAB, |
||||
| 200 | 26512681 |
CH |
||
Disease progression, Off label use, |
||||
PERTUZUMAB, TRASTUZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28